Stockscreener 앱 받기
10.00
4.38%
0.42
전일 마감가:
$9.58
열려 있는:
$9.6
하루 거래량:
383.13K
Relative Volume:
0.85
시가총액:
$705.67M
수익:
-
순이익/손실:
$-100.70M
주가수익비율:
-5.0761
EPS:
-1.97
순현금흐름:
$-86.54M
1주 성능:
+0.91%
1개월 성능:
+21.80%
6개월 성능:
-2.15%
1년 성능:
-0.20%
1일 변동 폭
$9.39
$10.14
1주일 범위
$9.39
$11.15
52주 변동 폭
$6.33
$16.65
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
ORIC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
10.00 | 705.67M | 0 | -100.70M | -86.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading Down 7.8%Should You Sell? - MarketBeat
Q2 EPS Estimate for ORIC Pharmaceuticals Reduced by Analyst - Defense World
Q2 EPS Forecast for ORIC Pharmaceuticals Reduced by Analyst - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Target Price at $18.29 - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Trading 10.9% HigherTime to Buy? - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat
Oric Pharmaceuticals announces clinical supply agreement with Janssen - Yahoo Finance
Barclays PLC Raises Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Buy Rating from HC Wainwright - Defense World
ORIC Pharmaceuticals (NASDAQ:ORIC) Receives Outperform Rating from Wedbush - Defense World
ORIC Pharmaceuticals advances cancer drug trials - Investing.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from Wedbush - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap UpHere's What Happened - MarketBeat
ORIC Pharmaceuticals' (ORIC) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
ORIC Pharmaceuticals, Inc. Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLCwith EGFR Exon 20 Insertion Mutations - Marketscreener.com
ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations - The Manila Times
ORIC® Pharmaceuticals Provides Early Phase 1b Combination - GlobeNewswire
ORIC Pharmaceuticals Announces Clinical Supply Agreement to - GlobeNewswire
ORIC Pharma's Cancer Drug Shows Strong Early Results, Partners With J&J for Lung Cancer Trial - StockTitan
ORIC Partners with Janssen to Test ORIC-114 Combo Therapy for First-Line NSCLC Treatment - StockTitan
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Buy" by Analysts - MarketBeat
ORIC Pharmaceuticals (STU:4TZ) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 8.8%Here's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by Jane Street Group LLC - Defense World
ORIC® Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
(ORIC) Proactive Strategies - Stock Traders Daily
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
ORIC Pharmaceuticals Awards Inducement Grants to New Employee, Including Stock Options - StockTitan
Geode Capital Management LLC Boosts Stake in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
Barclays PLC Has $1.10 Million Holdings in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
(ORIC) Trading Signals - Stock Traders Daily
EGFR-Non Small Cell Lung Cancer Market Predicted to See Upsurge Through 2032, Highlights DelveInsight | AstraZeneca, J&J Innovative Medicine, Hansoh Pharma, Cullinan Oncology, Taiho Pharma - The Globe and Mail
ORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap DownHere's Why - MarketBeat
ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Price Down 3.4%Should You Sell? - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by State Street Corp - Defense World
State Street Corp Trims Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Holdings Raised by Franklin Resources Inc. - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Shares Sold by XTX Topco Ltd - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $236,000 Stock Position in ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) - Defense World
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $18.29 Average Target Price from Analysts - Defense World
Brokerages Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Price Target at $18.29 - MarketBeat
Oric Pharmaceuticals CEO Chacko Jacob sells $204,214 in stock By Investing.com - Investing.com South Africa
Dominic Piscitelli Sells 8,851 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
Pratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock - MarketBeat
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) CEO Sells $204,184.80 in Stock - MarketBeat
Oric Pharmaceuticals chief medical officer sells $73,293 in stock - Investing.com India
Oric Pharmaceuticals chief medical officer sells $73,293 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals CFO sells $73,297 in stock - Investing.com India
Oric Pharmaceuticals CFO sells $73,297 in stock By Investing.com - Investing.com Australia
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Dec 16 '24 |
Sale |
8.28 |
8,851 |
73,298 |
106,764 |
| Multani Pratik S | Chief Medical Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
24,042 |
0 |
55,615 |
| Multani Pratik S | Chief Medical Officer |
Dec 16 '24 |
Sale |
8.28 |
8,850 |
73,293 |
46,765 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 15 '24 |
Option Exercise |
0.00 |
67,000 |
0 |
803,308 |
| Chacko Jacob | PRESIDENT AND CEO |
Dec 16 '24 |
Sale |
8.28 |
24,660 |
204,214 |
778,648 |
4.81%
자본화:
|
볼륨(24시간):